BMRABMRAHealthcare · Medical Devices

BMRA Stock Forecast: Biomerica, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.08
−1.82% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$5.0M
Ticker Nerd rank
11/ 100
Median analyst target
—
Analysts covering
—
Revenue$875K+16.8% y/y
Operating income−$1.5M
Net income−$1.1M
Free cash flow−$894K
Quarterly, 8 quarters to 31 May 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−20.6%
1M
−37.2%
YTD
−57.1%
1Y
−51.8%
From 52W high
−62.5%
From 52W low
0.0%
$1.08
$2.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Biomerica, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
11/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
40
Momentum
40
Accruals
34
Value
25
Growth
22
Revisions
20
Quality
18
Issuance
6

Volatility (40): The share price has been relatively steady.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BMRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00Jan 26Apr 26Jul 26Oct 26BMRA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Oct 2020Aegis CapitalMaintainsBuy$13 → $11
4 Sept 2020Aegis CapitalMaintainsBuy—
21 Aug 2020Aegis CapitalInitiatesBuy—
17 Dec 2018B. Riley FBRMaintainsBuy—
17 Dec 2018B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BMRA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BMRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Biomerica, Inc. returned −51.8% against +6.9% for the S&P 500, dividends included.

BMRA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26BMRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BMRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.1×

Cheaper than 62% of US stocks

Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
−8.1%

Higher than 3% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−113.8%

Higher than 12% of US stocks

Return on assets
−45.5%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biomerica, Inc. has a market value of $5.0M and an enterprise value of $4.6M.

  • Revenue in the twelve months to 31 May 2026: $4.5M. The latest quarter grew 16.8% year on year.

  • Net income over the same four quarters: −$3.8M, a −84.8% net margin.

  • Free cash flow in the twelve months to 31 May 2026: −$3.4M.

  • Shares outstanding: 3.1M.

  • forward P/E: 2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Biomerica, Inc. employs 50 people — $89K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 May 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

BMRA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BMRABiomerica, Inc.$5.0M11
WOKWORK Medical Technology Group Ltd.$4.9M16
BDMDBaird Medical Investment Holdings Ltd.$5.1M59
POASPhaos Technology Holdings (Cayman) Ltd.$5.1M2
INBSIntelligent Bio Solutions, Inc.$4.6M21
ICCMIceCure Medical Ltd.$4.5M30
VNRXVolitionRX Ltd.$5.8M53

Take a look at BMRA’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Biomerica, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BMRA

How does Ticker Nerd's model rank BMRA?

As at 21 Nov 2026, Biomerica, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (40 of 100).

What is the BMRA stock forecast for 2030?

No analyst covering Biomerica, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMRA are extrapolating price history, which says nothing about the business.

How has BMRA stock performed over the past year?

Biomerica, Inc. returned -51.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biomerica, Inc. do?

Biomerica Inc. is a biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products. The company’s portfolio centers on in-vitro diagnostic solutions used in point-of-care settings, physicians’ offices, and hospital and clinical laboratories.

Company

About Biomerica, Inc.

Biomerica Inc. is a biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products. The company’s portfolio centers on in-vitro diagnostic solutions used in point-of-care settings, physicians’ offices, and hospital and clinical laboratories. Its products address a range of medical conditions, with emphasis on gastrointestinal and inflammatory diseases, food intolerances, diabetes, and other diagnostic applications. Biomerica Inc. also serves clinical laboratory, physician office, home testing, and over-the-counter channels, supporting early detection and treatment decisions across multiple healthcare environments. Based in Irvine, California, the company operates as a specialized healthcare provider with a market presence in both diagnostic testing and therapeutic product development.

CEO Mr. Zackary S. Irani · 50 employees · United States · https://www.biomerica.com